BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067]
URL: https://www.wjgnet.com/1007-9327/full/v15/i17/2067.htm
(0) (0) (9148) (91)
Number Citing Articles
1
Maria Rojas-Feria, Mohammed Eslam, Manuel Castro-Fernández, Pedro Guerrero, Jose-Luis Larraona-Moreno, Manuel Romero-Gómez. Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. Journal of Crohn's and Colitis 2011; 5(6) doi: 10.1016/j.crohns.2011.04.015
2
Gert Van Assche, James D Lewis, Gary R Lichtenstein, Edward V Loftus, Qin Ouyang, Julian Panes, Corey A Siegel, William J Sandborn, Simon P L Travis, Jean-Frederic Colombel. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. American Journal of Gastroenterology 2011; 106(9) doi: 10.1038/ajg.2011.211
3
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis. Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. Intestinal Research 2021; 19(4) doi: 10.5217/ir.2020.00042
4
Mahdi Rahimi, Zahra Kariminezhad, Elsa-Patricia Rondon, Hassan Fahmi, Julio C. Fernandes, Mohamed Benderdour. Chitosan nanovectors for siRNA delivery: New horizons for nonviral gene therapy. Carbohydrate Polymers 2025; 360 doi: 10.1016/j.carbpol.2025.123581
5
Manuela Marzo, Carla Felice, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi. Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. Clinical Medicine Insights: Therapeutics 2011; 3 doi: 10.4137/CMT.S1978
6
Giovanni Casella, Vincenzo Villanacci, Camillo Di Bella, Elisabetta Antonelli, Vittorio Baldini, Gabrio Bassotti. Pulmonary diseases associated with inflammatory bowel diseases. Journal of Crohn's and Colitis 2010; 4(4) doi: 10.1016/j.crohns.2010.02.005
7
Carissa M. Thomas, Delphine M. A. Saulnier, Jennifer K. Spinler, Peera Hemarajata, Chunxu Gao, Sara E. Jones, Ashley Grimm, Miriam A. Balderas, Matthew D. Burstein, Christina Morra, Daniel Roeth, Markus Kalkum, James Versalovic. FolC2‐mediated folate metabolism contributes to suppression of inflammation by probiotic Lactobacillus reuteri. MicrobiologyOpen 2016; 5(5) doi: 10.1002/mbo3.371
8
Xinlong Wang, Weihua Xu, Yushan Wu, Peifeng Liu, Bing Wang, Jianfeng Li, Huili Dai. Clinical combination therapy for IBD and promising co-delivery strategies. Inflammopharmacology 2026; 34(6) doi: 10.1007/s10787-026-02222-5
9
Isabelle Cleynen, Wouter Van Moerkercke, Thomas Billiet, Pieter Vandecandelaere, Niels Vande Casteele, Christine Breynaert, Vera Ballet, Marc Ferrante, Maja Noman, Gert Van Assche, Paul Rutgeerts, Joost J. van den Oord, Ann Gils, Siegfried Segaert, Séverine Vermeire. Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Annals of Internal Medicine 2016; 164(1) doi: 10.7326/M15-0729
10
Tolga Sursal, Deborah J. Stearns-Kurosawa, Kiyoshi Itagaki, Sun-Young Oh, Shiqin Sun, Shinichiro Kurosawa, Carl J. Hauser. Plasma Bacterial and Mitochondrial DNA Distinguish Bacterial Sepsis From Sterile Systemic Inflammatory Response Syndrome and Quantify Inflammatory Tissue Injury in Nonhuman Primates. Shock 2013; 39(1) doi: 10.1097/SHK.0b013e318276f4ca
11
Isabelle Cleynen, Séverine Vermeire. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nature Reviews Gastroenterology & Hepatology 2012; 9(9) doi: 10.1038/nrgastro.2012.125
12
Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Jarosław Chmielnicki, Rafał Filip, Anna Pękala, Maria Janiak, Krzysztof Skrobot, Ewa Kasińska, Michał Krogulecki, Piotr Królikowski, Maria Kłopocka, Ariel Liebert, Elżbieta Poniewierka, Izabela Smoła, Anita Gąsiorowska, Aleksandra Kaczka, Joanna Wypych, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/17562848211036456
13
Raheleh Heydari, Mohammad Javad Tavassolifar, Mohammad Hossein Derakhshan Nazari, Romina Roshannia, Shabnam Shahrokh, Maryam Parvizi, Mohammad Tayefeh Norooz, Anna Meyfour, Raffaele Pellegrino. TUG1 and H19 lncRNAs Can Predict Anti‐TNF Unresponsiveness in Patients With Ulcerative Colitis: A Machine Learning–Based Approach. Mediators of Inflammation 2026; 2026(1) doi: 10.1155/mi/9078048
14
J. Présumey, G. Salzano, G. Courties, M. Shires, F. Ponchel, C. Jorgensen, F. Apparailly, G. De Rosa. PLGA microspheres encapsulating siRNA anti-TNFalpha: Efficient RNAi-mediated treatment of arthritic joints. European Journal of Pharmaceutics and Biopharmaceutics 2012; 82(3) doi: 10.1016/j.ejpb.2012.07.021
15
Bo Qiu, Jia-Xu Liang, Cong Li. Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Medicine 2022; 101(40) doi: 10.1097/MD.0000000000030590
16
Marianna Carone, Marianne R. Spalinger, Robert A. Gaultney, Raffaele Mezzenga, Kristýna Hlavačková, Aart Mookhoek, Philippe Krebs, Gerhard Rogler, Paola Luciani, Simone Aleandri. Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis. Nature Communications 2023; 14(1) doi: 10.1038/s41467-023-39013-3
17
Xue-Liang Jiang, Hui-Fei Cui, Jing Gao, Hua Fan. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. Journal of Clinical Gastroenterology 2015; 49(7) doi: 10.1097/MCG.0000000000000319
18
Abhik Bhattacharya, Daniel Travis, Mark T. Osterman, James D. Lewis, Bhavana Bhagya Rao, Helen Lee, Gary R. Lichtenstein. Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn’s Disease. Journal of Clinical Gastroenterology 2023; 57(1) doi: 10.1097/MCG.0000000000001637
19
Xiao-Qing Ji, Li-Xia Wang, De-Gan Lu. Pulmonary manifestations of inflammatory bowel disease. World Journal of Gastroenterology 2014; 20(37): 13501-13511 doi: 10.3748/wjg.v20.i37.13501
20
Hasan Hamam, Parambir S Dulai, John K Marshall, Christopher Ma, Vipul Jairath, Walter Reinisch, Neeraj Narula. Impact of concomitant corticosteroid use on adverse events in ulcerative colitis clinical trials. Journal of Crohn's and Colitis 2025; 19(8) doi: 10.1093/ecco-jcc/jjaf145
21
Z. Arora, B. Shen. Biological therapy for ulcerative colitis. Gastroenterology Report 2015; 3(2) doi: 10.1093/gastro/gou070
22
A. W. G. Waugh, S. Garg, K. Matic, L. Gramlich, C. Wong, D. C. Sadowski, M. Millan, R. Bailey, D. Todoruk, R. Cherry, C. W. Teshima, L. Dieleman, R. N. Fedorak. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort. Alimentary Pharmacology & Therapeutics 2010; 32(9) doi: 10.1111/j.1365-2036.2010.04446.x
23
Muhammad Abaidullah, Shaokai La, Mengqi Liu, Boshuai Liu, Yalei Cui, Zhichang Wang, Hao Sun, Sen Ma, Yinghua Shi. Polysaccharide from Smilax glabra Roxb Mitigates Intestinal Mucosal Damage by Therapeutically Restoring the Interactions between Gut Microbiota and Innate Immune Functions. Nutrients 2023; 15(19) doi: 10.3390/nu15194102
24
Jeff Chang, Rupert WL Leong. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2014; 14(1) doi: 10.1517/14712598.2014.853738
25
Shivaram Bhat, Divyesh Sharma, Pauline Doherty, Tony C.K. Tham, Grant R. Caddy. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?. Inflammatory Bowel Diseases 2010; 16(11) doi: 10.1002/ibd.21279
26
Bo Xiao, Qiubing Chen, Zhan Zhang, Lixin Wang, Yuejun Kang, Timothy Denning, Didier Merlin. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis. Journal of Controlled Release 2018; 287 doi: 10.1016/j.jconrel.2018.08.021
27
Ye Liu, Jinjian Huang, Sicheng Li, Ze Li, Canwen Chen, Guiwen Qu, Kang Chen, Yitian Teng, Rui Ma, Xiuwen Wu, Jianan Ren. Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review. Biomaterials Science 2024; 12(4) doi: 10.1039/D3BM01645E
28
Ernst Beinder, Thorsten Fischer, Dieter Grab, Thomas Grubert, Peer Hantschmann, Franz Kainer, Ralph Kästner, Christina Kentenich, Walter Klockenbusch, Reinhard Kopp, Frank Lammert, Frank Louwen, Ioannis Mylonas, Stephanie Pildner von Steinburg, Werner Rath, Ute M. Schäfer-Graf, Ekkehard Schleußner, Ralf Schmitz, Maximilian Sohn, Heinrich Otto Steitz. Facharzt Geburtsmedizin. 2012;  doi: 10.1016/B978-3-437-23751-5.10017-2
29
Xiang Xue, Sadeesh Ramakrishnan, Erik Anderson, Matthew Taylor, Ellen M. Zimmermann, Jason R. Spence, Sha Huang, Joel K. Greenson, Yatrik M. Shah. Endothelial PAS Domain Protein 1 Activates the Inflammatory Response in the Intestinal Epithelium to Promote Colitis in Mice. Gastroenterology 2013; 145(4) doi: 10.1053/j.gastro.2013.07.010
30
Sherman Picardo, Kenji So, Kannan Venugopal. Anti‐TNF‐induced lupus in patients with inflammatory bowel disease. JGH Open 2020; 4(3) doi: 10.1002/jgh3.12291
31
N Plevris, C S Chuah, R M Allen, I D Arnott, P N Brennan, S Chaudhary, A M D Churchhouse, S Din, E Donoghue, D R Gaya, M Groome, H M Jafferbhoy, P W Jenkinson, W L Lam, M Lyons, J C Macdonald, M MacMaster, C Mowat, G D Naismith, L F Potts, E Saffouri, J P Seenan, A Sengupta, P Shasi, D I Sutherland, J A Todd, J Veryan, A J M Watson, D A Watts, G R Jones, C W Lees. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Journal of Crohn's and Colitis 2019; 13(9) doi: 10.1093/ecco-jcc/jjz042
32
Christina Kriegel, Mansoor M Amiji. Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease. Clinical and Translational Gastroenterology 2011; 2(3) doi: 10.1038/ctg.2011.1
33
Jatinder P. Ahluwalia. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012; 96(3) doi: 10.1016/j.mcna.2012.04.009
34
Peng Zhang, Luting Lin, Ningrui Wang, Ying Wang, Yuqi Miao, Jun Fei, Qimiao Hu. Yougui pills prevent ovariectomy-induced bone loss by suppressing Th17 response and IL-17/NF-κB pathway. Annals of Medicine 2025; 57(1) doi: 10.1080/07853890.2025.2529576
35
Ruixia Li, Xiaofei Li, He Zhou, Yanting Shi, Fang Wang, Tong Wu, Jie Liang. Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1205046
36
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2009; 18(12) doi: 10.1002/pds.1655
37
Ellen A. Lipstein, Maria T. Britto. Evolution of Pediatric Chronic Disease Treatment Decisions. Medical Decision Making 2015; 35(6) doi: 10.1177/0272989X15581805
38
Büşra Başer Taşkın, Ayşenur Doğru Kılınç, Muhammed Talha Karadoğan, Figen Çakmak, Fatma Gül Demirkan, Nuray Aktay Ayaz. Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey. Expert Opinion on Biological Therapy 2025; 25(11) doi: 10.1080/14712598.2025.2597849
39
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J Sandborn. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry. American Journal of Gastroenterology 2012; 107(9) doi: 10.1038/ajg.2012.218
40
Victor Klimyuk, Gregory Pogue, Stefan Herz, John Butler, Hugh Haydon. Plant Viral Vectors. Current Topics in Microbiology and Immunology 2012; 375 doi: 10.1007/82_2012_212
41
Orestis Ioannidis, Angeliki Cheva, Ioannis Varnalidis, Ioannis Koutelidakis, Vasileios Papaziogas, Panagiotis Christidis, Elissavet Anestiadou, Konstantinos Aggelopoulos, Ioannis Mantzoros, Manousos George Pramateftakis, Efstathios Kotidis, Barbara Driagka, Stamatios Aggelopoulos, Evangelos J. Giamarellos-Bourboulis. The Combined Administration of Eicosapentaenoic Acid (EPA) and Gamma-Linolenic Acid (GLA) in Experimentally Induced Colitis: An Experimental Study in Rats. Journal of Clinical Medicine 2024; 13(22) doi: 10.3390/jcm13226661
42
Raymond K. Cross. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. Inflammatory Bowel Diseases 2017; 23(10) doi: 10.1097/MIB.0000000000001261
43
Giorgia Bodini, Maria Giulia Demarzo, Margherita Saracco, Claudia Coppo, Costanza De Maria, Isabella Baldissarro, Edoardo Savarino, Vincenzo Savarino, Edoardo G. Giannini. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2019; 54(10) doi: 10.1080/00365521.2019.1666914
44
Sebastian Strobel, Maria T. Abreu. Biologic Therapy in Inflammatory Bowel Disease—A Gastrointestinal Perspective. Seminars in Colon and Rectal Surgery 2012; 23(2) doi: 10.1053/j.scrs.2012.02.007
45
Silvio Danese, Kavitha Subramaniam, Jan Van Zyl, Shashi Adsul, Dirk Lindner, Jeannine Roth, Séverine Vermeire. Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme. Alimentary Pharmacology & Therapeutics 2021; 53(2) doi: 10.1111/apt.16160
46
Husain Attarwala, Mansoor Amiji. Handbook of Polyester Drug Delivery Systems. 2016;  doi: 10.1201/b20045-14
47
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Current Gastroenterology Reports 2020; 22(9) doi: 10.1007/s11894-020-00781-3
48
Dejun Cui, Guomei Huang, Daping Yang, Bo Huang, Bangquan An. Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2013; 37(5) doi: 10.1016/j.clinre.2012.12.004
49
Ellen A. Lipstein, Cassandra M. Dodds, Daniel J. Lovell, Lee A. Denson, Maria T. Britto. Making decisions about chronic disease treatment: a comparison of parents and their adolescent children. Health Expectations 2016; 19(3) doi: 10.1111/hex.12210
50
Roberta Elisa Rossi, Ioanna Parisi, Edward John Despott, Andrew Kenneth Burroughs, James O'Beirne, Dario Conte, Mark Ian Hamilton, Charles Daniel Murray. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World Journal of Gastroenterology 2014; 20(46): 17352-17359 doi: 10.3748/wjg.v20.i46.17352
51
Min Kyoung Cho, Mi Kyung Park, Shin Ae Kang, Seon Hee Choi, Soon Cheol Ahn, Hak Sun Yu. Trichinella spiralis Infection Suppressed Gut Inflammation with CD4+CD25+Foxp3+T Cell Recruitment. The Korean Journal of Parasitology 2012; 50(4) doi: 10.3347/kjp.2012.50.4.385
52
Steffen Dan‐Nielsen, Vibeke Wewer, Anders Paerregaard, Lars F. Hansen, Rasmus G. Nielsen, Aksel Lange, Christian Jakobsen. Does Infliximab Prevent Colectomy in Acute and Chronic Active Ulcerative Colitis?. Journal of Pediatric Gastroenterology and Nutrition 2014; 58(6) doi: 10.1097/MPG.0000000000000340
53
Paulina Núñez F, Rodrigo Quera, Constanza Bay, Fabiola Castro, Gabriel Mezzano. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2022; 16(7) doi: 10.1093/ecco-jcc/jjac013
54
Mark Löwenberg, Xander G Vos, Laura Jansen. Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitis. World Journal of Clinical Cases 2016; 4(2): 60-62 doi: 10.12998/wjcc.v4.i2.60
55
Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuki Toyokawa, Makoto Tanaka, Yuma Hotta, Kazuhiro Kamada, Takeshi Ishikawa, Hideyuki Konishi, Mitsuo Kishimoto, Yuji Naito, Yoshito Itoh. Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01709-5
56
Christina Kriegel, Mansoor Amiji. Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. Journal of Controlled Release 2011; 150(1) doi: 10.1016/j.jconrel.2010.10.002
57
Yifei Wang, Zhiying Wang, Pengfei Lou, Hong Ni, Yang Yang, Guangyao Chen, Shuxin Zhang. Research Trends and Hotspots in JAK Inhibitors for Ulcerative Colitis: A Bibliometric Analysis From 2015 to 2024. Journal of Multidisciplinary Healthcare 2025;  doi: 10.2147/JMDH.S548268
58
Tripti Khare, Sushesh Srivatsa Palakurthi, Brijesh M. Shah, Srinath Palakurthi, Sharad Khare. Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel Disease. International Journal of Molecular Sciences 2020; 21(11) doi: 10.3390/ijms21113956
59
Fanny Giron, Anna Pastó, Ennio Tasciotti, Bincy P Abraham. Nanotechnology in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; 25(12) doi: 10.1093/ibd/izz205
60
Martin Luchtefeld, Tarek Jalouta. Anorectal Disease. 2016;  doi: 10.1007/978-3-319-23147-1_6
61
Sam C. Nalle, Jerrold R. Turner. Biology and Regulation of Blood-Tissue Barriers. Advances in Experimental Medicine and Biology 2013; 763 doi: 10.1007/978-1-4614-4711-5_5
62
Honghui Zhou, Yan Xu, Amarnath Sharma. Pharmaceutical Biotechnology. 2019;  doi: 10.1007/978-3-030-00710-2_26
63
Ankita Wal, Pranay Wal, Deependra Singh, Manju Rawat Singh. Nanocarriers Based Colon Targeting. 2025;  doi: 10.1016/B978-0-443-24806-1.00024-8
64
Honghui Zhou, Zhenhua Xu, Mary Ann Mascelli, Hugh M. Davis. Pharmaceutical Biotechnology. 2013;  doi: 10.1007/978-1-4614-6486-0_20
65
Husain Attarwala, Murui Han, Jonghan Kim, Mansoor Amiji. Oral nucleic acid therapy using multicompartmental delivery systems. WIREs Nanomedicine and Nanobiotechnology 2018; 10(2) doi: 10.1002/wnan.1478
66
Jeffrey B. Brown, Paul Cheresh, Zheng Zhang, Hyunji Ryu, Elizabeth Managlia, Terrence A. Barrett. P-Selectin Glycoprotein Ligand-1 Is Needed for Sequential Recruitment of T-Helper 1 (Th1) and Local Generation of Th17 T Cells in Dextran Sodium Sulfate (DSS) Colitis. Inflammatory Bowel Diseases 2012; 18(2) doi: 10.1002/ibd.21779
67
Chunbai He, Lichen Yin, Yudong Song, Cui Tang, Chunhua Yin. Optimization of multifunctional chitosan–siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in rats. Acta Biomaterialia 2015; 17 doi: 10.1016/j.actbio.2015.01.041
68
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Wayne Langholff, Anil Londhe, William J Sandborn. Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry. American Journal of Gastroenterology 2014; 109(2) doi: 10.1038/ajg.2013.441
69
Kinga Majchrzak, Jakub Fichna. Biologic Therapy in Crohn’s Disease–What We Have Learnt So Far. Current Drug Targets 2020; 21(8) doi: 10.2174/1389450121666191218123203
70
Koji Sono, Akihiro Yamada, Yasushi Yoshimatsu, Nobuo Takada, Yasuo Suzuki. Factors associated with the loss of response to infliximab in patients with Crohn’s disease. Cytokine 2012; 59(2) doi: 10.1016/j.cyto.2012.04.026
71
Angelo V. Marzano, Alessandro Borghi, Pier Luigi Meroni, Carlo Crosti, Massimo Cugno. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014; 47(3) doi: 10.3109/08916934.2013.873414
72
Palpandi Pandi, Anjali Jain, Saka Raju, Wahid Khan. Therapeutic Approaches for the Delivery ofTNF-αsiRNA. Therapeutic Delivery 2017; 8(5) doi: 10.4155/tde-2017-0011
73
Sung Won Jang, Min Kyoung Cho, Mi Kyung Park, Shin Ae Kang, Byoung-Kuk Na, Soon Cheol Ahn, Dong-Hee Kim, Hak Sun Yu. Parasitic Helminth Cystatin Inhibits DSS-Induced Intestinal Inflammation Via IL-10+F4/80+Macrophage Recruitment. The Korean Journal of Parasitology 2011; 49(3) doi: 10.3347/kjp.2011.49.3.245
74
Christina Kriegel, Husain Attarwala, Mansoor Amiji. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Advanced Drug Delivery Reviews 2013; 65(6) doi: 10.1016/j.addr.2012.11.003
75
Ellen A. Lipstein, Daniel J. Lovell, Lee A. Denson, David W. Moser, Shehzad A. Saeed, Cassandra M. Dodds, Maria T. Britto. Parents' Information Needs in Tumor Necrosis Factor‐α Inhibitor Treatment Decisions. Journal of Pediatric Gastroenterology and Nutrition 2013; 56(3) doi: 10.1097/MPG.0b013e31827496c3
76
H. Sales-Campos, P.J. Basso, V.B.F. Alves, M.T.C. Fonseca, G. Bonfá, V. Nardini, C.R.B. Cardoso. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research 2015; 48(2) doi: 10.1590/1414-431x20143774
77
Annemay M. H. Stoker, Leslie Logghe, Mirjam C. M. van der Ende-van Loon, Erik J. Schoon, Ramon-Michel Schreuder, Arnold Stronkhorst, Lennard P. L. Gilissen. Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clinical and Experimental Medicine 2023; 23(6) doi: 10.1007/s10238-023-00994-6
78
Fernando Magro, Francisco Portela. Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies. BioDrugs 2010; 24 doi: 10.2165/11586290-000000000-00000
79
Yan Xu, Jia Chen, Honghui Zhou. Pharmaceutical Biotechnology. 2024;  doi: 10.1007/978-3-031-30023-3_24
80
Bernard Bizzini, Béatrice Drouet, Daniel Zagury, Marc Abitbol, Arsène Burny, Marie-Christophe Boissier. Kinoids: A Family of Immunogens for Active Anticytokine Immunotherapy Applied to Autoimmune Diseases and Cancer. Immunotherapy 2010; 2(3) doi: 10.2217/imt.10.16
81
Laura Janssen, Mariëlle Romberg-Camps, Ad van Bodegraven, Jeoffrey Haans, Michèl Aquarius, Paul Boekema, Tamara Munnecom, Lloyd Brandts, Manuela Joore, Adrian Masclee, D Jonkers, M Pierik. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial. BMJ Open 2021; 11(5) doi: 10.1136/bmjopen-2020-042885
82
S. He, T. Li, H. Chen, W. Ma, Q. Yao, H. Yang, H. Wang, F. Wang, C. Zhao, P. Yang. CD14+ cell-derived IL-29 modulates proinflammatory cytokine production in patients with allergic airway inflammation. Allergy 2011; 66(2) doi: 10.1111/j.1398-9995.2010.02455.x
83
Lucianna Motta Correia, Danielle Queiroz Bonilha, Juliana Dantas Ramos, Orlando Ambrogini, Sender Jankiel Miszputen. Treatment of inflammatory bowel disease and pregnancy: a review of the literature. Arquivos de Gastroenterologia 2010; 47(2) doi: 10.1590/S0004-28032010000200016
84
Thomas W. Lee, Richard N. Fedorak. Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. Gastroenterology Clinics of North America 2010; 39(3) doi: 10.1016/j.gtc.2010.08.018
85
Gregory P. Pogue, Fakhrieh Vojdani, Kenneth E. Palmer, Ernie Hiatt, Steve Hume, Jim Phelps, Lori Long, Natasha Bohorova, Do Kim, Michael Pauly, Jesus Velasco, Kevin Whaley, Larry Zeitlin, Stephen J. Garger, Earl White, Yun Bai, Hugh Haydon, Barry Bratcher. Production of pharmaceutical‐grade recombinant aprotinin and a monoclonal antibody product using plant‐based transient expression systems. Plant Biotechnology Journal 2010; 8(5) doi: 10.1111/j.1467-7652.2009.00495.x
86
Isabel Nawroth, Jan Alsner, Mark A. Behlke, Flemming Besenbacher, Jens Overgaard, Kenneth A. Howard, Jørgen Kjems. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosis. Radiotherapy and Oncology 2010; 97(1) doi: 10.1016/j.radonc.2010.09.010
87
Ryoki Takahashi, Takayasu Noguchi, Yoko Mizoguchi, Tadashi Shimoyama, Teruko Nakazawa, Tohru Ikuta. A Synbiotic with Tumor Necrosis Factor-αInhibitory Activity Ameliorates Experimental Jejunoileal Mucosal Injury. BioMed Research International 2018; 2018 doi: 10.1155/2018/9184093
88
Cristhiane Favero de Aguiar, Angela Castoldi, Vinícius Andrade-Oliveira, Aline Ignacio, Flávia Franco da Cunha, Raphael José Ferreira Felizardo, Ênio José Bassi, Niels Olsen Saraiva Câmara, Danilo Candido de Almeida. Mesenchymal stromal cells modulate gut inflammation in experimental colitis. Inflammopharmacology 2018; 26(1) doi: 10.1007/s10787-017-0404-6
89
Christine L. Schuler, Cassandra Dodds, Kevin A. Hommel, Richard F. Ittenbach, Lee A. Denson, Ellen A. Lipstein. Shared decision making in IBD: A novel approach to trial consent and timing. Contemporary Clinical Trials Communications 2019; 16 doi: 10.1016/j.conctc.2019.100447
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.